RCUS (Arcus Biosciences) FCF Margin %: -811.76% (As of Mar. 2026)


RCUS Arcus Biosciences Inc RCUS
46 GF Score
Price $28.80
GF Value $13.85
Valuation Significantly Overvalued
! 6 Warning Signs
View Full Analysis

What is Arcus Biosciences FCF Margin %?

Arcus Biosciences RCUS +2.20% 46 FCF Margin % is -811.76% as of Mar. 2026. GuruFocus rates RCUS with a GF Score™ of 46/100 and a GF Value™ of $13.85 (Significantly Overvalued). The stock has 6 warning signs investors should review. Among 959 Biotechnology companies, Arcus Biosciences ranks worse than 61.11% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Arcus Biosciences's Free Cash Flow for the three months ended in Mar. 2026 was $-138.0 Mil. Arcus Biosciences's Revenue for the three months ended in Mar. 2026 was $17.0 Mil. Therefore, Arcus Biosciences's FCF Margin % for the quarter that ended in Mar. 2026 was -811.76%.

As of today, Arcus Biosciences's current FCF Yield % is -13.47%.

The historical rank and industry rank for Arcus Biosciences's FCF Margin % or its related term are showing as below:

RCUS' s FCF Margin % Range Over the Past 10 Years
Min: -2163.69   Med: -195.95   Max: 385.71
Current: -206.78

During the past 10 years, the highest FCF Margin % of Arcus Biosciences was 385.71%. The lowest was -2163.69%. And the median was -195.95%.

RCUS's FCF Margin % is ranked worse than
61.11% of 959 companies
in the Biotechnology industry
Industry Median: -84.65 vs RCUS: -206.78

Arcus Biosciences FCF Margin % Related Terms

Arcus Biosciences FCF Margin % Historical Data

* Premium members only.

The historical data trend for Arcus Biosciences's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Arcus Biosciences FCF Margin % Chart

Arcus Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -73.63 385.71 -282.05 -68.22 -195.95

Arcus Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -475.00 -83.13 -373.08 -363.64 -811.76

RCUS vs TNGX, DYN, RLAY: FCF Margin % Comparison

For the Biotechnology subindustry, Arcus Biosciences's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Arcus Biosciences FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Arcus Biosciences's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Arcus Biosciences's FCF Margin % falls into.


RCUS
46GF Score
Arcus Biosciences Inc RCUS
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Arcus Biosciences FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Arcus Biosciences's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-484/247
=-195.95 %

Arcus Biosciences's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-138/17
=-811.76 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -811.76% mean?
Arcus Biosciences (RCUS) has a FCF Margin % of -811.76% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Arcus Biosciences and its competitors. According to the industry distribution chart, Arcus Biosciences ranks #586 out of 959 companies in the Biotechnology industry, placing it in the top 61.1%.
Is Arcus Biosciences' FCF Margin % too high?
Arcus Biosciences' current FCF Margin % is -811.76%. Based on the distribution chart, Arcus Biosciences ranks #586 out of 959 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Arcus Biosciences has a GF Score™ of 46/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Arcus Biosciences' FCF Margin % compare to TNGX and DYN?
According to the Biotechnology industry distribution chart, Arcus Biosciences ranks #586 out of 959 companies for FCF Margin %. This places Arcus Biosciences in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Arcus Biosciences and its competitors. Arcus Biosciences's current FCF Margin % is -811.76%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Arcus Biosciences stock overvalued right now?
Based on GuruFocus' analysis, Arcus Biosciences (RCUS) is currently considered Significantly Overvalued. The stock's GF Value™ is $13.85, compared to a current price of $28.80 — trading 107.9% above its estimated fair value. The current FCF Margin % is -811.76%. Arcus Biosciences' overall GF Score™ is 46/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Arcus Biosciences (RCUS), the current FCF Margin % is -811.76% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Arcus Biosciences (RCUS) Overvalued in 2026?

Based on GuruFocus' analysis, Arcus Biosciences stock appears to be overvalued. The current stock price of $28.80 is trading 107.9% above its estimated GF Value™ of $13.85. GuruFocus considers Arcus Biosciences to be Significantly Overvalued.

Key valuation signals for RCUS:

  • FCF Margin %: -811.76%
  • GF Value™: $13.85 vs. price of $28.80 (107.9% above fair value)
  • GF Score™: 46/100 with 6 warning signs

No single metric tells the full story. See the RCUS stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Arcus Biosciences Business Description

Address 3928 Point Eden Way, Hayward, CA, USA, 94545
Arcus Biosciences Inc is a late clinical-stage biopharmaceutical company focused on developing differentiated molecules for patients with cancer and inflammatory and autoimmune diseases. Its product pipeline includes Domvanalimab, Quemliclustat, Casdatifan, Zimberelimab, among others. The company operates in one reportable and operating segment, which is the business of developing and commercializing differentiated therapies.
46GF Score

Get the complete analysis for RCUS

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$28.80
Price
$13.85
GF Value